Evaluation after five years of the cancer genetic counselling programme of Valencian Community (Eastern Spain)

Familial Cancer
Dolores Cuevas-Cuerda, Dolores Salas-Trejo


To evaluate the cancer genetic counselling programme in Valencian Community using intermediate indicators. Descriptive analysis of organisational and effectiveness indicators from the start in 2005 until December 2010: correct referral of patients according to the area from where they were referred (primary or hospital-based care) and syndrome; families identified as having each syndrome; suitability of the genetic testing for individuals with a cancer diagnosis (index cases, IC) and relatives of ICs with mutations; family size; and results of genetic testing on genes, ICs and relatives. 9,942 individuals attended, 87.7 % were referred by hospital-based care and 8.4 % by primary care. 7,516 patients (79 %) fulfilled cancer genetic counselling criteria (82 % from hospital-based care and 46 % from primary care). Amongst those who fulfilled the criteria, 59 % of referrals were related to hereditary breast ovarian cancer syndrome and 32 % to hereditary non-polyposis colorectal cancer. ICs were found in 3,082 families (78.7 %) and genetic testing was carried out on 91.3 % of them. Pathogenic mutations were detected in 21.8 % of the ICs and the testing was then offered to their relatives (an average of 3 per IC). Pathogenic mutations...Continue Reading


Apr 15, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·UNKNOWN American Society of Clinical Oncology
Jan 14, 2004·European Journal of Human Genetics : EJHG·Béatrice GodardSégolène Aymé
Aug 28, 2004·Community Genetics·P HopwoodC Julian-Reynier
Jun 9, 2006·Journal of Genetic Counseling·UNKNOWN National Society of Genetic Counselors' Definition Task ForceJanet L Williams
May 2, 2007·International Journal of Cancer. Journal International Du Cancer·M J Bermejo-PérezA Llanos-Méndez
May 31, 2007·European Journal of Human Genetics : EJHG·Mark KroeseJoanne Whittaker
Apr 29, 2008·Bulletin of the World Health Organization·Anne AndermannVéronique Déry
Jan 13, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mark E RobsonUNKNOWN American Society of Clinical Oncology
Feb 24, 2010·Journal of Health Services Research & Policy·Anne AndermannVéronique Déry
Apr 1, 2010·The American Journal of Gastroenterology·Elena M StoffelSapna Syngal
Sep 21, 2010·Familial Cancer·Mel WisemanSusan Michie
Feb 18, 2012·The Cochrane Database of Systematic Reviews·Jennifer S HilgartRachel Iredale
Aug 23, 2012·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·Enrique Lastra-ArasJuan-Jesús Cruz

❮ Previous
Next ❯


Jun 16, 2016·Frontiers in Psychiatry·Francisco López-Muñoz, Esther Cuerda-Galindo
Dec 5, 2018·The British Journal of General Practice : the Journal of the Royal College of General Practitioners·Flore LaforestAdrian Edwards
Jul 24, 2021·BMC Medical Genomics·Himika GuptaGovindasamy Kumaramanickavel

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer: BRCA1 & BRCA2

Mutations involving BRCA1, found on chromosome 17, and BRCA2, found on chromosome 13, increase the risk for specific cancers, such as breast cancer. Discover the last research on breast cancer BRCA1 and BRCA2 here.

Autoimmune Polyendocrine Syndromes

This feed focuses on a rare genetic condition called Autoimmune Polyendocrine Syndromes, which are characterized by autoantibodies against multiple endocrine organs. This can lead to Type I Diabetes.